News
FDA rejects Amgen/UCB osteoporosis drug
The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a potential cardiac safety risk.
Monday 7 April 2025
